As we begin a new year and reflect on the accomplishments of 2015, we continue to focus on our efforts to fulfill FARE’s mission; to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. We are proud of the impact that FARE is making and we are grateful for the generosity of our supporters and volunteers.
While our legacy organizations were founded in the 1990s, FARE itself was established just three years ago. Our organization’s focus has evolved dramatically, but one thing that has not changed is our commitment to achieving accommodations for patients with food allergies and our support for food allergy research.
In 2015 specifically, FARE made tremendous strides into food allergy education, advocacy and awareness. Last year, we:
- Reached millions of people worldwide through our award-winning website
- Provided free, comprehensive information packets to 35,000 people with newly diagnosed food allergies
- Launched the FARE College Food Allergy Program in 12 schools
- Supported 50 local education and awareness initiatives through our Community Outreach Grants
- Hosted record-breaking annual meetings; the FARE Teen Summit and the FARE National Food Allergy Conference
- Conducted 12 monthly educational webinars
- Promoted food allergy awareness through 60 nationwide FARE Walk for Food Allergy events
- Helped states implement laws on stock epinephrine in schools
- Supported efforts to pass legislation requiring food allergy training in restaurants
- Championed the Airline Access to Emergency Epinephrine Act to make food allergic people safe when they fly
- Lead awareness initiatives, including FARE’s Teal Pumpkin Project™
FARE also is the world’s largest private funder of food allergy research, having invested approximately $80 million to date toward finding life-changing treatments and studying this potentially life-threatening disease. This includes funding research in many areas of treatment, such as oral immunotherapy, as well as in epidemiology, etiology, and the economic and psychosocial impact of this public health problem.
Under the leadership of Dr. James R. Baker Jr., who now serves as FARE’s CEO and Chief Medical Officer, FARE committed over $7 million to research in 2015 that included:
- An investment of $2.5 million for the new FARE Investigator in Food Allergy Awards, designed to attract talented mid-career and new researchers to the field of food allergy. You can read the details of these scientists’ work here. FARE expects to accept proposals for a new cycle of awards later this year and to announce recipients in 2017.
- The initial $2.5 million yearly investment for the FARE Clinical Network, which will promote the sharing of best practices, elevate the level of clinical care for patients with food allergies and accelerate the development of life-changing therapeutics in ways that single researchers and centers cannot accomplish alone.
- The lead sponsorship of a consensus study by the Institute of Medicine that will serve as a comprehensive report on the state of food allergy.
Additionally, last year we saw study results published in prestigious journals for FARE-funded research including the groundbreaking LEAP study, and we convened our third Research Retreat, bringing together 80 researchers, senior government officials, industry representatives and food allergy advocates from around the world for a series of discussions critical toward advancing food allergy research.
And that’s just a snapshot of the work we did in 2015. More details of our work can be found here.
All of us at FARE are incredibly grateful for the support of our donors who made possible these efforts on behalf of the food allergy community. We look forward to more shared accomplishments in 2016 and beyond.